Bavarian unconcerned by Moderna RSV advance: ”It's completely as expected"

Bavarian Nordic is not worried by the news that Moderna has announced a phase III trial of its RSV vaccine, positioning the US-based firm ahead of the Danish one in the race to reach the potentially lucrative RSV market. ”Old news,” says VP of Investor Relations & Communications Rolf Sass Sørensen.

Photo: Philip Davali/Ekstra Bladet, Philip Davali

Another competitor is now breathing down Bavarian Nordic’s neck, as Moderna announced its next step after a successful phase II with its vaccine against respiratory syncytial virus (RSV) on Tuesday.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs